US 11,987,634 B2
Antibodies specific for CD70 and their uses
Siler Panowski, Berkeley, CA (US); Tao Sai, Foster City, CA (US); Barbra Johnson Sasu, San Francisco, CA (US); Surabhi Srivatsa Srinivasan, San Francisco, CA (US); and Thomas John Van Blarcom, Oakland, CA (US)
Assigned to PFIZER INC., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Jun. 1, 2022, as Appl. No. 17/830,324.
Application 17/830,324 is a division of application No. 16/264,485, filed on Jan. 31, 2019, granted, now 11,377,500.
Claims priority of provisional application 62/641,873, filed on Mar. 12, 2018.
Claims priority of provisional application 62/625,019, filed on Feb. 1, 2018.
Prior Publication US 2023/0002498 A1, Jan. 5, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2875 (2013.01) [A61P 35/00 (2018.01); C07K 16/2809 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 33 Claims
 
1. An isolated antibody, which specifically binds to Cluster of Differentiation 70 (CD70), wherein the antibody comprises a heavy chain variable (VH) region comprising a VH complementarity determining region one (CDR1), a VH CDR2, and a VH CDR3, and a light chain variable (VL) region comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein:
the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 428,
the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 431,
the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 433; or
the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 429,
the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 432,
the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 433; or
the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 430,
the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 431,
the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 433; and
wherein
the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 512,
the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 513, and
the VL CDR3 comprises the amino acid sequence of SEQ ID NO: 514.